The Centers for Medicare & Medicaid Services (CMS) released a draft decision that stated that while the use of beta amyloid PET does exclude the possibility of Alzheimer’s Disease, the current evidence is insufficient to warrant coverage for everyone enrolled in Medicare. In response, the Medical Imaging & Technology Alliance (MITA) released a statement saying they are, “concerned that CMS considers the existing evidence inadequate for coverage for all Medicare beneficiaries.” The statement added that MITA determined the evidence to be sufficient.
The CMS proposal would cover one PET beta amyloid scan per patient and only if the patient is enrolled in a CMS-approved clinical trial.
